Home › Research › Costs and economics
Estimated Annual Spending on Aducanumab in the US Medicare Program
John N Mafi, Mei Leng, Julia Cave Arbanas, Chi-Hong Tseng, Cheryl L Damberg, Catherine Sarkisian, Bruce E Landon. JAMA health forum, 2022-01-14
Topic: Drug trials: efficacy and safety
This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.
Key findings
- This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designcross-sectional
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 27 of the 56 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (JAMA health forum) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35977233) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 27 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 27 of the 56 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Mafi, J. N., Leng, M., Arbanas, J. C., Tseng, C.-H., Damberg, C. L., Sarkisian, C., et al. (2022). Estimated Annual Spending on Aducanumab in the US Medicare Program. JAMA health forum. https://doi.org/10.1001/jamahealthforum.2021.4495
Vancouver
Mafi JN, Leng M, Arbanas JC, Tseng C.-H, Damberg CL, Sarkisian C, et al. Estimated Annual Spending on Aducanumab in the US Medicare Program. JAMA health forum. 2022. doi:10.1001/jamahealthforum.2021.4495. PMID: 35977233.
BibTeX
@article{mafi2022-35977233,
author = {Mafi, John N and Leng, Mei and Arbanas, Julia Cave and Tseng, Chi-Hong and Damberg, Cheryl L and Sarkisian, Catherine and Landon, Bruce E},
title = {{Estimated Annual Spending on Aducanumab in the US Medicare Program}},
journal = {JAMA health forum},
year = {2022},
doi = {10.1001/jamahealthforum.2021.4495},
pmid = {35977233},
url = {https://doi.org/10.1001/jamahealthforum.2021.4495}
}
Related studies in Costs and economics
Also tagged “costs”
265 studies in the library carry the topic tag “costs”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 265 tagged studies.